Vigonvita Life Sciences Sets 28 Aug 2026 Board Meeting to Approve H1 Results and Consider Interim Dividend

Bulletin Express08-18

Vigonvita Life Sciences has announced that its board of directors will convene on 28 August 2026 to review and approve the Group’s interim results for the six months ended 30 June 2026. The agenda also includes deliberation on the declaration of an interim dividend and other routine matters.

The meeting will be chaired by Dr. Tian Guanghui, who serves as Chairman, Executive Director, Chief Executive Officer and General Manager. The current board comprises two executive directors (Dr. Tian Guanghui and Dr. Hu Tianwen), one non-executive director (Mr. Liu Haoxuan) and three independent non-executive directors (Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi).

Vigonvita Life Sciences is a joint-stock company incorporated in the People’s Republic of China and listed on the Hong Kong Stock Exchange under the stock name VIGONVITA-B (02630). Further details, including the approved interim financial statements and any dividend declaration, are expected to be released following the board meeting.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198012611?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-18 16:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198012611","market":"us","top_or_hot":-1,"title":"Vigonvita Life Sciences Sets 28 Aug 2026 Board Meeting to Approve H1 Results and Consider Interim Dividend","media":"Bulletin Express","content":"<p>Vigonvita Life Sciences has announced that its board of directors will convene on 28 August 2026 to review and approve the Group’s interim results for the six months ended 30 June 2026. The agenda also includes deliberation on the declaration of an interim dividend and other routine matters.</p>\n<p>The meeting will be chaired by Dr. Tian Guanghui, who serves as Chairman, Executive Director, Chief Executive Officer and General Manager. The current board comprises two executive directors (Dr. Tian Guanghui and Dr. Hu Tianwen), one non-executive director (Mr. Liu Haoxuan) and three independent non-executive directors (Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi).</p>\n<p>Vigonvita Life Sciences is a joint-stock company incorporated in the People’s Republic of China and listed on the Hong Kong Stock Exchange under the stock name VIGONVITA-B (02630). Further details, including the approved interim financial statements and any dividend declaration, are expected to be released following the board meeting.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vigonvita Life Sciences Sets 28 Aug 2026 Board Meeting to Approve H1 Results and Consider Interim Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVigonvita Life Sciences Sets 28 Aug 2026 Board Meeting to Approve H1 Results and Consider Interim Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-18 16:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vigonvita Life Sciences has announced that its board of directors will convene on 28 August 2026 to review and approve the Group’s interim results for the six months ended 30 June 2026. The agenda also includes deliberation on the declaration of an interim dividend and other routine matters.</p>\n<p>The meeting will be chaired by Dr. Tian Guanghui, who serves as Chairman, Executive Director, Chief Executive Officer and General Manager. The current board comprises two executive directors (Dr. Tian Guanghui and Dr. Hu Tianwen), one non-executive director (Mr. Liu Haoxuan) and three independent non-executive directors (Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi).</p>\n<p>Vigonvita Life Sciences is a joint-stock company incorporated in the People’s Republic of China and listed on the Hong Kong Stock Exchange under the stock name VIGONVITA-B (02630). Further details, including the approved interim financial statements and any dividend declaration, are expected to be released following the board meeting.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02630","symbol_name":"旺山旺水-B","start_time":0,"source_url":"","article_id":"1198012611","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198012611","pubTimestamp":1787042876,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Vigonvita Life Sciences has announced that its board of directors will convene on 28 August 2026 to review and approve the Group’s interim results for the six months ended 30 June 2026. The agenda...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02630":"旺山旺水-B"},"translate_title":"Vigonvita Life Sciences 定于 2026 年 8 月 28 日召开董事会会议，批准上半年业绩并考虑中期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02630":1},"content_text":"Vigonvita Life Sciences has announced that its board of directors will convene on 28 August 2026 to review and approve the Group’s interim results for the six months ended 30 June 2026. The agenda also includes deliberation on the declaration of an interim dividend and other routine matters.\nThe meeting will be chaired by Dr. Tian Guanghui, who serves as Chairman, Executive Director, Chief Executive Officer and General Manager. The current board comprises two executive directors (Dr. Tian Guanghui and Dr. Hu Tianwen), one non-executive director (Mr. Liu Haoxuan) and three independent non-executive directors (Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi).\nVigonvita Life Sciences is a joint-stock company incorporated in the People’s Republic of China and listed on the Hong Kong Stock Exchange under the stock name VIGONVITA-B (02630). Further details, including the approved interim financial statements and any dividend declaration, are expected to be released following the board meeting.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198012611","isCrawlerRequest":true}